These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 36242805)

  • 1. AQP4-IgG-positive neuromyelitis optica spectrum disorder and temporally detected neoplasms: case report and systematic review.
    Apiraksattayakul N; Songwisit S; Owattanapanich W; Tisavipat N; Siritho S; Prayoonwiwat N; Rattanathamsakul N; Jitprapaikulsan J
    Mult Scler Relat Disord; 2022 Dec; 68():104212. PubMed ID: 36242805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aquaporin-4-IgG positive neuromyelitis optica spectrum disorder in a paraneoplastic context.
    Hyun JW; Park NY; Kim MJ; Kim H; Kim KH; Kim SH; Kim HJ
    J Neurol Sci; 2023 Nov; 454():120825. PubMed ID: 37813018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigating paraneoplastic aquaporin-4-IgG-seropositive neuromyelitis optica spectrum disorder through a data-driven approach.
    Dinoto A; Borin GU; Campana G; Carta S; Ferrari S; Mariotto S
    Eur J Neurol; 2022 Nov; 29(11):3466-3472. PubMed ID: 35767391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical profile of patients with paraneoplastic neuromyelitis optica spectrum disorder and aquaporin-4 antibodies.
    Sepúlveda M; Sola-Valls N; Escudero D; Rojc B; Barón M; Hernández-Echebarría L; Gómez B; Dalmau J; Saiz A; Graus F
    Mult Scler; 2018 Nov; 24(13):1753-1759. PubMed ID: 28920766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Familial neuromyelitis optica spectrum disorders: Case series and systematic review.
    Wannaphut C; Ongphichetmetha T; Satiraphan P; Jitprapaikulsan J; Apiwattanakul M; Siritho S; Prayoonwiwat N; Savangned P; Rattanathamsakul N
    Mult Scler Relat Disord; 2023 May; 73():104627. PubMed ID: 37015139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term Effectiveness and Safety of Rituximab in Neuromyelitis Optica Spectrum Disorder and MOG Antibody Disease.
    Barreras P; Vasileiou ES; Filippatou AG; Fitzgerald KC; Levy M; Pardo CA; Newsome SD; Mowry EM; Calabresi PA; Sotirchos ES
    Neurology; 2022 Nov; 99(22):e2504-e2516. PubMed ID: 36240094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AQP4-IgG-seropositive neuromyelitis optica spectrum disorder (NMOSD) coexisting with anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis: A case report and literature review.
    Tao S; Zhang Y; Ye H; Guo D
    Mult Scler Relat Disord; 2019 Oct; 35():185-192. PubMed ID: 31398657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical characteristics of late-onset neuromyelitis optica spectrum disorder.
    Min W; Zhang L; Wang S; Xue M; Guo C; Zhu M
    Mult Scler Relat Disord; 2023 Feb; 70():104517. PubMed ID: 36708681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The relationship between aquaporin-4 antibody status and visual tract integrity in neuromyelitis optica spectrum disorders: A visual evoked potential study.
    Barć K; Gospodarczyk-Szot K; Nojszewska M; Podlecka-Piętowska A; Zakrzewska-Pniewska B
    Mult Scler Relat Disord; 2020 Sep; 44():102265. PubMed ID: 32575026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Newly diagnosed neuromyelitis optica spectrum disorders following vaccination: Case report and systematic review.
    Anamnart C; Tisavipat N; Owattanapanich W; Apiwattanakul M; Savangned P; Prayoonwiwat N; Siritho S; Rattanathamsakul N; Jitprapaikulsan J
    Mult Scler Relat Disord; 2022 Feb; 58():103414. PubMed ID: 35216789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of anti-aquaporin 4 antibody in a diagnostic cohort of patients being investigated for possible neuromyelitis optica spectrum disorder in Western Australia.
    Fabis-Pedrini MJ; Bundell C; Wee CK; Lucas M; McLean-Tooke A; Mastaglia FL; Carroll WM; Kermode AG
    J Neuroimmunol; 2018 Nov; 324():76-80. PubMed ID: 30248527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short myelitis lesions in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorders.
    Flanagan EP; Weinshenker BG; Krecke KN; Lennon VA; Lucchinetti CF; McKeon A; Wingerchuk DM; Shuster EA; Jiao Y; Horta ES; Pittock SJ
    JAMA Neurol; 2015 Jan; 72(1):81-7. PubMed ID: 25384099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and paraclinical profile of neuromyelitis optic spectrum disorder in a peruvian cohort.
    Castro-Suarez S; Guevara-Silva E; Osorio-Marcatinco V; Alvarez-Toledo K; Meza-Vega M; Caparó-Zamalloa C
    Mult Scler Relat Disord; 2022 Aug; 64():103919. PubMed ID: 35691236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paraneoplastic AQP4-IgG-Seropositive Neuromyelitis Optica Spectrum Disorder Associated With Teratoma: A Case Report and Literature Review.
    Ikeguchi R; Shimizu Y; Shimomura A; Suzuki M; Shimoji K; Motohashi T; Yamamoto T; Shibata N; Kitagawa K
    Neurol Neuroimmunol Neuroinflamm; 2021 Jul; 8(5):. PubMed ID: 34285095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overlap syndrome of anti-aquaporin-4 positive neuromyelitis optica spectrum disorder and systemic lupus erythematosus: A systematic review of individual patient data.
    Kopp CR; Prasad CB; Naidu S; Sharma V; Misra DP; Agarwal V; Sharma A
    Lupus; 2023 Sep; 32(10):1164-1172. PubMed ID: 37487596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Longitudinal evaluation of clinical characteristics of Chinese neuromyelitis optica spectrum disorder patients with different AQP4-IgG serostatus.
    Zhang X; Liu X; Yu H; Deng B; Zhang Y; Chen X
    Mult Scler Relat Disord; 2022 Jun; 62():103786. PubMed ID: 35429818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Age at onset predicts outcome in aquaporin-4-IgG positive neuromyelitis optica spectrum disorder from a United Kingdom population.
    Papathanasiou A; Tanasescu R; Tench CR; Rocha MF; Bose S; Constantinescu CS; Jacob S
    J Neurol Sci; 2021 Dec; 431():120039. PubMed ID: 34715481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Actual issues of serum aquaporin-4 autoantibodies evaluation in the diagnostics of neuromyelitis optica spectrum disorders].
    Krasnov VS; Totolyan NA; Nazarov VD; Mazing AV; Makshakov GS; Lapin SV; Evdoshenko EP; Skoromets AA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2020; 120(7. Vyp. 2):24-31. PubMed ID: 32844626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The temporal relationship of paraneoplastic aquaporin-4-IgG seropositive neuromyelitis optica spectrum disorder (NMOSD) and breast cancer: a systematic review and meta-analysis.
    Srichawla BS; Doshi K; Cheraghi SN; Sivakumar S
    Neurol Sci; 2023 Nov; 44(11):3809-3817. PubMed ID: 37453952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The risk factors of neuropathic pain in neuromyelitis optica spectrum disorder: a retrospective case-cohort study.
    Li X; Xu H; Zheng Z; Ouyang H; Chen G; Lou Z; Chen H; Zhang J; Zhan Y; Mao H; Zhang C; Zhao M; Zhao Y
    BMC Neurol; 2022 Aug; 22(1):304. PubMed ID: 35986246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.